HM 101207
Alternative Names: HM-101207Latest Information Update: 02 Jul 2025
At a glance
- Originator Hanmi Pharmaceutical
- Class Antineoplastics
- Mechanism of Action KRAS protein inhibitors; SOS1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 25 Apr 2025 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Hanmi Pharmaceutical plans IND enabling GLP-toxicity studies to support further clinical trial in Cancer
- 14 Apr 2025 Preclinical trials in Cancer in South Korea (PO), prior to April 2025